Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Financing › Details

4SC–Yorkville Group: credit, 201403 first tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd


Period Period 2014-03-04
  Predecessor 4SC–Yorkville Group: credit, 201402– up to nominally €15m convertible notes to be purchased until 12/16 by YA Global Master SPV Ltd
  Successor 4SC–Yorkville Group: credit, 201409 second tranche €500k convertible notes under up to €15m agreem from 2/14 w YA Global Master SPV Ltd
Organisations Money taker 4SC AG
  Group 4SC (Group)
  Money source YA Global Master SPV Ltd.
  Group Yorkville Group (Group)
Products Product small-molecule drug
  Product 2 finance
  Index term 2 4SC–Yorkville Group: credit, 201402– up to nominally €15m convertible notes to be purchased until 12/16 by YA Global Master SPV Ltd

4SC AG. (3/4/14). "Press Release: 4SC AG Issues First Tranche of Convertible Notes with a Nominal amount of EUR 500,000 to Yorkville". Planegg-Martinsried.

Planegg-Martinsried, 4 March 2014 - 4SC AG (Frankfurt, Prime Standard: VSC) today announced that it successfully completed the issuance of convertible notes with a nominal amount of EUR 500,000.00. These convertible notes constitute the first tranche of a total issuance of up to EUR 15 million guaranteed by an agreement between YA Global Master SPV Ltd. ("Yorkville") and the Company. Following the successful conversion of previously issued tranches, the Company's Management will decide independently on a case-by-case basis whether additional tranches will be issued.

Excluding the pre-emptive rights of existing shareholders, the notes will be issued exclusively to Yorkville at a subscription price corresponding to 95% of the nominal amount. The notes carry no interest, have a term of nine month and may be converted into shares of 4SC by the holder of the notes at any time. The conversion price equals the volume weighted average trading price of 4SC shares during a five-day period prior to the time of conversion, less a 5% discount, but it cannot be lower than EUR 1.13.

Further details regarding the terms and conditions in connection with the issuance of convertible notes according to the agreement with Yorkville were announced in the ad hoc release dated 12 February 2014.

Ad hoc ends


Information and Explaination of the Issuer to this News:

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 78 employees (57 FTEs) at 30 September 2013. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit or contact:

Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at), Tel.: +49-89-7007-6366

MC Services
Raimund Gabriel
raimund.gabriel(at) , Tel.: +49-89-2102-2830

The Trout Group
Chad Rubin
crubin(at), Tel.: +1-646-378-2947

Record changed: 2017-04-02


Picture BioM Forum Translationl Medicine 2018 Würzburg Germany iito 600x100px

More documents for 4SC (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital RegMed Forum 2018 October iito 600x60px

» top